Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone in major depression: a controlled study.

K Rickels1, J D Amsterdam, C Clary

  • 1Department of Psychiatry, University of Pennsylvania, Philadelphia.

The Journal of Clinical Psychiatry
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peel bond strength between 3D printing tray materials and elastomeric impression/adhesive systems: A laboratory study.

Dental materials : official publication of the Academy of Dental Materials·2020
Same author

Comparative evaluation of topographical data of dental implant surfaces applying optical interferometry and scanning electron microscopy.

Dental materials : official publication of the Academy of Dental Materials·2017
Same author

Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.

Acta psychiatrica Scandinavica·2016
Same author

Coating of ß-tricalcium phosphate scaffolds-a comparison between graphene oxide and poly-lactic-co-glycolic acid.

Biomedical materials (Bristol, England)·2015
Same author

The role of current literature in psychiatric residency education.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
Same author

Cytocompatibility evaluation of different biodegradable magnesium alloys with human mesenchymal stem cells.

Journal of materials science. Materials in medicine·2013
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Buspirone significantly improved major depression with anxiety compared to placebo over 8 weeks. This medication was well-tolerated and safe, showing promising results for patients with moderate depression and anxiety.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is a prevalent mental health condition often co-occurring with anxiety.
  • Anxiety symptoms can complicate the diagnosis and treatment of depression.
  • Identifying effective and well-tolerated pharmacological interventions for comorbid depression and anxiety is crucial.

Purpose of the Study:

  • To compare the efficacy and safety of buspirone versus placebo in treating outpatients with major depression and moderate anxiety.
  • To evaluate treatment response rates after 8 weeks of therapy.

Main Methods:

  • A double-blind, placebo-controlled study involving 155 outpatients diagnosed with major depression and moderate anxiety.
  • Participants received either buspirone or placebo for 8 weeks.

Related Experiment Videos

  • Treatment outcomes were assessed using physician- and patient-completed measures.

    • Main Results:

    • Buspirone treatment demonstrated significantly greater efficacy than placebo at the 8-week endpoint.
    • Seventy percent of patients receiving buspirone showed moderate to marked improvement, compared to 35% in the placebo group (p < .01).
    • Treatment discontinuation rates were 34% for buspirone and 41% for placebo. Initial anxiety and depression severity did not impact treatment outcomes. Buspirone was safe and well-tolerated up to 90 mg/day.

    Conclusions:

    • Buspirone is an effective and well-tolerated treatment option for major depression with moderate anxiety.
    • The medication shows a significant advantage over placebo in improving depressive symptoms.
    • Further research can explore optimal dosing and long-term effects in this patient population.